lung cancer

You have access
Significant Contribution of Interleukin-18 Genotypes to Lung Cancer Risk in Taiwanese
MENG-FENG WU, LI-HSIOU CHEN, NING-YI HSIA, YI-CHENG SHEN, TE-CHUN SHEN, ZHI-HONG WANG, YA-CHEN YANG, YUN-CHI WANG, WEN-SHIN CHANG, TE-CHUN HSIA, DA-TIAN BAU and CHIA-WEN TSAI

Anticancer Research July 2022, 42 (7) 3381-3387; DOI: https://doi.org/10.21873/anticanres.15825
Open Access
Stereotactic Body Radiotherapy for Stage I Lung Cancer With a New Real-time Tumor Tracking System
YUICHI HIROSHIMA, YOSHIO TAMAKI, TAKUYA SAWADA, TOSHIKI ISHIDA, KENJI YASUE, KAZUYA SHINODA, TAKASHI SAITO, TAKAYUKI KABURAGI, MORIYUKI KIYOSHIMA, TOSHIYUKI OKUMURA and HIDEYUKI SAKURAI

Anticancer Research June 2022, 42 (6) 2989-2995; DOI: https://doi.org/10.21873/anticanres.15782
Open Access
Prognostic Implication of PD-L1 Expression on Osimertinib Treatment for EGFR-mutated Non-small Cell Lung Cancer
TOSHIHIRO SHIOZAWA, TAKESHI NUMATA, TOMOHIRO TAMURA, TAKEO ENDO, TAKAYUKI KABURAGI, YUSUKE YAMAMOTO, HIDEYASU YAMADA, NORIHIRO KIKUCHI, KAZUHITO SAITO, MASAHARU INAGAKI, KOICHI KURISHIMA, YASUNORI FUNAYAMA, KUNIHIKO MIYAZAKI, NOBUYUKI KOYAMA, KINYA FURUKAWA, HIROYUKI NAKAMURA, SHINJI KIKUCHI, HIDEO ICHIMURA, YUKIO SATO, IKUO SEKINE, HIROAKI SATOH and NOBUYUKI HIZAWA

Anticancer Research May 2022, 42 (5) 2583-2590; DOI: https://doi.org/10.21873/anticanres.15736
You have access
Estimating the Probability of Not Completing the Intended Course of Thoracic Radiotherapy for Lung Cancer
DIRK RADES, ESTHER GLATZEL, SABINE BOHNET, STEVEN E. SCHILD and ELISA M. WERNER

Anticancer Research April 2022, 42 (4) 1973-1977; DOI: https://doi.org/10.21873/anticanres.15675
You have access
Can Previous Chemotherapy Affect the Outcome of Nivolumab Treatment in Non-small Cell Lung Cancer?
MARTIN SVATON, MONIKA BRATOVA, LEONA KOUBKOVA, ONDREJ FISCHER, BOHUSLAV MELICHAR, MICHAL HRNCIARIK, DANIEL DOLEZAL, ONDREJ BILEK, JANA KREJCI, MARIE DROSSLEROVA, ZDENKA DLOUHA, JIRI BLAZEK, PETRA MAJKOVA, LUCIE BROZOVA and MAREK STASTNY

Anticancer Research April 2022, 42 (4) 1987-1995; DOI: https://doi.org/10.21873/anticanres.15677
You have access
A Prognostic Tool to Estimate the Risk of Pneumonitis in Patients Irradiated for Lung Cancer
ESTHER GLATZEL, ELISA M. WERNER, SABINE BOHNET and DIRK RADES

Anticancer Research April 2022, 42 (4) 2029-2032; DOI: https://doi.org/10.21873/anticanres.15683
You have access
Real-world Afatinib Outcomes in Advanced Non–small Cell Lung Cancer Harboring EGFR Mutations
CHI-HAN CHEN, JOHN WEN-CHENG CHANG, CHING-FU CHANG, CHEN-YANG HUANG, CHENG-TA YANG, CHIH-HSI SCOTT KUO, YUEH-FU FANG, PING-CHIH HSU and CHIAO-EN WU

Anticancer Research April 2022, 42 (4) 2145-2157; DOI: https://doi.org/10.21873/anticanres.15697
You have access
Annexin A10 Expression as a Novel Prognostic Marker in Lung Adenocarcinoma
MASAKO YUMURA, TATSUYA NAGANO, NAOE JIMBO, RYOTA DOKUNI, TATSUNORI KIRIU, YUGO TANAKA, MOTOKO TACHIHARA, TOMOO ITOH, YOSHIMASA MANIWA, YOSHIHIRO NISHIMURA and KAZUYUKI KOBAYASHI

Anticancer Research March 2022, 42 (3) 1289-1294; DOI: https://doi.org/10.21873/anticanres.15595
You have access
Laboratory Parameters Associated With Inflammation Do Not Affect PD-L1 Expression in Non-small Cell Lung Cancer
MARTIN SVATON, MARIE DROSSLEROVA, ONDREJ FISCHER, MILOSLAV MAREL, MICHAL HRNCIARIK, ONDREJ VENCLICEK, PETR ZUNA, MICHAL SVOBODA, JIRI BLAZEK, MONIKA BRATOVA, ANDREA MULLEROVA, BOHUSLAVA VANKOVA and DANIEL KREJCI

Anticancer Research March 2022, 42 (3) 1563-1569; DOI: https://doi.org/10.21873/anticanres.15630
You have access
Administration of Gapmer-type Antisense Oligonucleotides Targeting γ-Glutamylcyclotransferase Suppresses the Growth of A549 Lung Cancer Xenografts
HIROMI II, YUUYA KASAHARA, HARUMI YAMAGUMA, SUSUMU KAGEYAMA, AKIHIRO KAWAUCHI, SATOSHI OBIKA and SUSUMU NAKATA

Anticancer Research March 2022, 42 (3) 1221-1227; DOI: https://doi.org/10.21873/anticanres.15589

Main menu

User menu

Search

lung cancer

Pages